Wendy Smith Begolka

Wendy Smith Begolka

Auto-generated profile, based on publicly available information

Wendy Smith Begolka

National Eczema Association, 505 San Marin Drive, #B300, Novato, CA 94945, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Dermatitis®
Verified
Journal Article
Open access
WBWendy Mbs Smith Begolka
Wendy Mbs Smith Begolka
RCRaj Chovatiya
Raj Chovatiya
ITIsabelle J. Thibau
Isabelle J. Thibau
JSJonathan Silverberg
Jonathan Silverberg
Background Atopic dermatitis (AD) is associated with considerable financial cost. However, the full burden of out-of-pocket (OOP) expenses is not well understood. Objective We sought to characterize the OOP health care expenses associated with AD management. Methods A 25-question voluntary online survey was administered to National Eczema Association members worldwide (n = 113,502). Inclusion criteria (US residents age ≥18 years who either self-reported had AD or were primary caregivers of individuals with AD) were met by 77.3% (1118/1447) of respondents. Results Respondents reported OOP expenses in 3 categories: (1) health care providers and prescriptions, including health care provider visit deductibles (68.7% [686]), prescription co-pays (64.3% [635]), and prescriptions not covered by insurance (48.6% [468]); (2) nonprescription health care products, including moisturizers (94.3% [934]), hygiene products (85.0% [824], allergy medications (75.1% [715]), itch relievers (68.25% [647]), dietary supplements (52.2% [491]), and sleep aids (37.0% [336]); and (3) complementary approaches, including cleaning products (74.7% [732]), clothing/bedding (44.8% [430]), alternative medications (19.0% [180]), and adjunctive therapies (15.9% [150]). The median annual AD OOP expense was US $600 (range, US $0–$200,000), with 41.9% (364) reporting expenditures US $1000 or greater. Conclusions Out-of-pocket expenses place a significant financial burden on individuals with AD. Additional studies are needed to better understand associations and impact of OOP costs.

14 June 2023 in Pediatric Dermatology
Verified
Journal Article
Open access
ESElaine Siegfried
Elaine Siegfried
LALisa M. Arkin
Lisa M. Arkin
YCYvonne E. Chiu
Yvonne E. Chiu
AHAdelaide A. Hebert
Adelaide A. Hebert
JCJeffrey P. Callen
Jeffrey P. Callen
HBHeather A. Brandling‐Bennett
Heather A. Brandling‐Bennett
Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide variety of indications since then. However, despite widespread off‐label use, FDA labeling does not include approved indications for the use of MTX for many inflammatory skin diseases in pediatric patients, including morphea, psoriasis, atopic dermatitis, and alopecia areata, among others. Without published treatment guidelines, some clinicians may be hesitant to use MTX off‐label, or uncomfortable prescribing MTX in this population. To address this unmet need, an expert consensus committee was convened to develop evidence‐ and consensus‐based guidelines for use of MTX to treat pediatric inflammatory skin disease. Clinicians with experience and expertise in clinical research, drug development, and treating inflammatory skin disease in pediatric patients with MTX were recruited. Five committees were created based on major topic areas: (1) indications and contraindications, (2) dosing, (3) interactions with immunizations and medications, (4) adverse effects (potential for and management of), and (5) monitoring needs. Pertinent questions were generated and addressed by the relevant committee. The entire group participated in a modified Delphi process to establish agreement on recommendations for each question. The committee developed 46 evidence‐ and consensus‐based recommendations, each with >70% agreement among members, across all five topics. These are presented in tables and text, along with a discussion of supporting literature, and level of evidence. These evidence‐ and consensus‐based recommendations will support safe and effective use of MTX for the underserved population of pediatric patients who may benefit from this valuable, time‐honored medication.

27 September 2021 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
RCRaj Chovatiya
Raj Chovatiya
WBWendy Smith Begolka
Wendy Smith Begolka
ITIsabelle J. Thibau
Isabelle J. Thibau
JSJonathan Silverberg
Jonathan Silverberg
Black race is associated with increased atopic dermatitis (AD) severity and healthcare resource utilization. However, the burden of out-of-pocket (OOP) expenses among black individuals with AD is not well understood. We sought to characterize the categories and impact of OOP healthcare expenses associated with AD management among black individuals. A 25-question voluntary online survey was administered to National Eczema Association members (N = 113,502). Inclusion criteria (US residents age ≥ 18 years; self-report of AD or primary caregivers of individuals with AD) was met by 77.3% (1118/1447) of respondents. Black individuals with AD were younger, had lower household income, Medicaid, urban residence, poor AD control and frequent skin infections (P ≤ 0.02). Blacks vs. non-blacks reported more OOP costs for prescription medications covered (74.2% vs. 63.6%, P = 0.04) and not covered (65.1% vs. 46.5%, P = 0.0004) by insurance, emergency room visits (22.1% vs. 11.8%, P = 0.005), and outpatient laboratory testing (33.3% vs. 21.8%, P = 0.01). Black race was associated with increased household financial impact from OOP expenses (P = 0.0009), and predictors of financial impact included minimally controlled AD (adjusted OR [95% CI] 13.88 [1.63–117.96], P = 0.02), systemic therapy (4.34 [1.63–11.54], 0.003), > $200 monthly OOP expenses (14.28 [3.42–59.60], P = 0.0003), and Medicaid (4.02 [1.15–14.07], P = 0.03). Blacks with Medicaid had higher odds of harmful financial impact (3.32 [1.77–6.24], P = 0.0002) than those of black race (1.81 [1.04–3.15], P = 0.04) or with Medicaid (1.39 [1.02–1.88], P = 0.04) alone. Black race is associated with increased OOP costs for AD and significant household financial impact. Targeted interventions are needed to address financial disparities in AD.

6 July 2022 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
ITIsabelle J. Thibau
Isabelle J. Thibau
ALAllison R. Loiselle
Allison R. Loiselle
ELEmile Latour
Emile Latour
EFErin Foster
Erin Foster
WBWendy Smith Begolka
Wendy Smith Begolka
Eczema is a term that encompasses a group of conditions that cause the skin to become itchy and inflamed. National estimates for the prevalence of eczema indicate that 1 in 10 individuals will be affected by eczema at some point in their lifetime.1 Atopic dermatitis, the most common form of eczema, can have both pediatric and adult onset.2-4 After initial presentation, eczema can be continuous for many years, or it can show a relapsing-remitting nature.3 Disease severity, specific phenotypes of the disease, triggers for flares, and quality-of-life effects are extremely patient-specific, necessitating an individualized treatment approach. The patient journey to achieving desired care experience and outcomes can additionally be challenging, time consuming, and negatively affect overall burden of disease.5-7

18 October 2021 in Dermatitis®
Verified
Journal Article
Open access
RCRaj Chovatiya
Raj Chovatiya
WBWendy Smith Begolka
Wendy Smith Begolka
ITIsabelle J. Thibau
Isabelle J. Thibau
JSJonathan Silverberg
Jonathan Silverberg
The aim of the study was to characterize the impact and associations of OOP health care expenses for AD. A 25-question online survey was administered to National Eczema Association members (N = 113,502). Inclusion criteria (US residents aged ≥18 years; self-reported AD or primary caregiver of individual with AD) were met by 77.3% (1118 of 1447). Respondents with monthly OOP expenses greater than $200 were more likely to have increased AD severity, flares, health care provider visits, prescription polypharmacy, use of step-up therapy, frequent skin infections, and poorer disease control (P < 0.005 for all). Respondents with OOP yearly expenditures greater than $1000 had similar associations and additionally increased rates of comorbid asthma, allergic rhinitis, and anxiety/depression (P < 0.005 for all). A total of 64.6% (n = 624) reported harmful household financial impact of OOP expenses. Predictors of harmful impact included severe AD (adjusted odds ratio [95% confidence interval], 2.62 [1.11–6.19], P = 0.04), comorbid asthma (1.42 [1.07–1.87], P = 0.03), 5 health care provider visits or more in a year (2.80 [1.62–4.82], P = 0.0007), greater than $200 OOP monthly expenditures (2.16 [1.45–3.22], 0.0006), and $1000 annual OOP expenditures or more (4.56 [3.31–6.27], P < 0.0001). Out-of-pocket expenses for AD significantly impact household finances. Clinical interventions are needed to minimize OOP expenses while optimizing care outcomes. Capsule Summary: • Atopic dermatitis (AD) is associated with significant financial cost, including increased out-of-pocket (OOP) expenses, although the impact and associations of OOP health care expenses for AD management are not well understood. • The OOP health care expenses related to AD are associated with increased disease severity and health care utilization and significantly impact the household finances of patients and caregivers. • Health care providers should be mindful of the OOP financial burden related to AD management and engage in shared decision making to create a treatment plan that is practical and effective and minimizes household financial impact.

1 October 2024 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
ADAaron M. Drucker
Aaron M. Drucker
ITIsabelle J. C. Thibau
Isabelle J. C. Thibau
BMBryan Mantell
Bryan Mantell
KDKatie N. Dainty
Katie N. Dainty
MWMatthew Wyke
Matthew Wyke
WBWendy Smith Begolka
Wendy Smith Begolka
Importance: Flare is a term commonly used in atopic dermatitis (AD) care settings and clinical research, but little consensus exists on what it means. Meanwhile, flare management is an important unmet research and treatment need. Understanding how various therapies might comparatively improve AD flares as a measure of treatment effectiveness may facilitate shared decision-making and enable assessment of effectiveness within and outside clinical settings.Objective: To identify patient-reported attributes associated with an AD flare to develop a patient-centered, consensus-based working definition.Design, Setting, and Participants: This consensus survey study used a modified eDelphi method involving consensus-building focus groups and a survey conducted from January 10 through October 24, 2023. Focus groups were conducted virtually, and the online survey was advertised to National Eczema Association members. US adults aged 18 years or older with AD were recruited via convenience sampling.Exposure: Lived experience of AD.Main Outcomes and Measures: The main outcome was consensus on which attributes of AD to include in a patient-centric definition of flare. Using a rating scale (range, 1-9), consensus for the modified eDelphi statement rating was defined as at least 70% of participants rating a statement as 7 to 9 (critical to a flare definition) and less than 15% rating it as 1 to 3 (not important).Results: Twenty-six participants with AD who completed focus group activities (24 aged 18-44 years [92.3%] and 2 aged 45-64 years [7.7%]; 18 women [69.2%]) and 631 participants with AD (mean [SD] age, 45.5 [18.1] years; 533 women [84.5%]) who completed the survey were included in the analysis. Fifteen statements reached consensus from the focus groups, and of those, 12 reached consensus from survey participants. More than half (334 of 631 [52.9%]) of survey participants reported alignment with their health care practitioner on what a flare is, and most (478 of 616 [77.6%]) reported that a patient-centered definition would be useful when communicating with their health care practitioner about their condition.Conclusions and Relevance: In this study, participants with AD reached consensus on what an AD flare means from the patient perspective. This understanding may improve research and care by addressing this key patient-centered aspect of evaluating treatment effectiveness.